about
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primatesVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesEffective post-exposure treatment of Ebola infectionDurability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primatesDevelopment of a new vaccine for the prevention of Lassa fever.Lassa fever in post-conflict sierra leoneMutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcomeProposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviationsEbola haemorrhagic feverMultiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreakTargeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR PathwayAnimal models for highly pathogenic emerging virusesPanmicrobial Oligonucleotide Array for Diagnosis of Infectious DiseasesThe Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathwayThe Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic VirusesInhibition of heat-shock protein 90 reduces Ebola virus replicationRescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNAMost neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunitsIsolation and characterization of a novel gammaherpesvirus from a microbat cell lineDevelopment of Prototype Filovirus Recombinant Antigen ImmunoassaysImmune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPsLabel-free multiplexed virus detection using spectral reflectance imaging.Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirusDetection and identification of Variola virus in fixed human tissue after prolonged archival storage.Neutralizing antibody fails to impact the course of Ebola virus infection in monkeysDevelopment of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.Enhanced light microscopy visualization of virus particles from Zika virus to filamentous ebolaviruses.Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event.Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus.Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatmentVector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primatesAccelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.Medical research: Ebola therapy protects severely ill monkeys.Vesicular stomatitis virus-based vaccines against Lassa and Ebola virusesDeep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells.Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.
P50
Q21090120-8B496C7E-05A4-4F82-B33C-A254F7F9CE95Q21131585-BA54AA17-13D5-4440-B11F-F8AEEE4A3AF4Q21131616-8C2F7E30-DA8D-4AB3-8434-5F50F11B0A98Q21559476-91B8F285-3F8A-4EEF-9366-F70BBFE61DD7Q21563440-D4E2D586-E598-4D70-BF82-9D0ED6A131DDQ24290732-3361E49A-2401-493C-A6C0-136D1AB2F29FQ24310145-8DCD5D2E-5D65-4EB1-971E-F7B1215A5AAEQ24620453-2AEBD3C7-45A3-4778-9457-7295AC12B5CEQ24629338-25DFD0C5-D2DE-4AE3-A087-FB83214C5DA5Q24701722-355C0A8A-1ACE-47B8-8E42-26215724E882Q26700090-E27B243F-BA13-4E1B-8970-E1A92B557BEEQ27004147-7448ADC5-792E-4EB7-98F9-3051DE944782Q27489133-180B1CCC-3FFE-484B-B3DD-8EFFF090EF08Q27682227-296F9E3A-1C2C-4CC9-9EBB-D38E341D24BCQ28271798-B9F97B07-1247-44A8-A663-94A4091CF7B2Q28281834-23EA188A-4CC6-4350-B616-0823355BCB88Q28396399-99A037FE-DE9C-4E9E-8E3F-B668C2D55B55Q28602816-C9158973-9439-4DF4-8797-306C5F1D09F1Q28602952-CBA96329-88F6-4B7A-92D2-358534A8C2B0Q28607807-6B08D825-6E2E-4101-AEC0-1B18349106F3Q28768041-5FE37AD8-9AA3-44AC-9835-687AA260B434Q30468513-2B21ADE6-FAC1-4380-82C0-28621BB3094DQ30724121-D59C3AF2-CEC0-48AC-8E2F-93426CE946D9Q31027770-EC731BC9-7827-426B-BFD6-4A8FC2663C3CQ33269796-EE275AF6-9748-4E73-ADC2-3254EB1C62BBQ33587327-7B4628E5-2261-4AE1-B582-C704F4F81FF5Q33834669-B1B7FDAF-6138-4098-9910-B3DE4318C803Q33974171-E2B3A5E5-9FC7-4E02-93BA-BB79DABB9140Q33974706-00D7A560-711E-4930-AAC3-954EA6CCCF88Q33981963-F01125E4-C2FC-4310-B737-FDF07E9771DAQ33987611-E0DDDF39-34EA-429C-9E73-CA724B18FC7AQ34022606-52B2EE36-3502-4482-8C9E-52D81AA8ABE8Q34120677-FA68D579-2A18-452D-8DD3-A8541F3FB21FQ34120895-44525A8A-0BBA-49CF-B5B3-478642D1FDF3Q34220503-F4C9F8F4-7ECB-475C-A7ED-0F53EF52D751Q34292954-9E0AD179-63BA-4CAA-B47D-9B13C25BF161Q34435933-6874A7EE-4BCE-4837-BAD5-3CCE62EEB975Q34459935-32BAC4C0-8983-45AD-BCAE-143FC8804162Q34461912-F0D33482-4A29-4BBB-9AB2-E9905F02CC2EQ34473079-559F7AC7-6879-462C-AB7B-99C4ED61BBF3
P50
name
Thomas W Geisbert
@ast
Thomas W Geisbert
@en
Thomas W Geisbert
@nl
type
label
Thomas W Geisbert
@ast
Thomas W Geisbert
@en
Thomas W Geisbert
@nl
prefLabel
Thomas W Geisbert
@ast
Thomas W Geisbert
@en
Thomas W Geisbert
@nl